250 related articles for article (PubMed ID: 29696636)
21. Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors.
Gao Y; Bergman I
J Virol; 2023 Jun; 97(6):e0037223. PubMed ID: 37199666
[TBL] [Abstract][Full Text] [Related]
22. Targeting and killing of metastatic cells in the transgenic adenocarcinoma of mouse prostate model with vesicular stomatitis virus.
Moussavi M; Tearle H; Fazli L; Bell JC; Jia W; Rennie PS
Mol Ther; 2013 Apr; 21(4):842-8. PubMed ID: 23337981
[TBL] [Abstract][Full Text] [Related]
23. Prediction and validation of murine MHC class I epitopes of the recombinant virus VSV-GP.
Vijver SV; Danklmaier S; Pipperger L; Gronauer R; Floriani G; Hackl H; Das K; Wollmann G
Front Immunol; 2022; 13():1100730. PubMed ID: 36741416
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors.
Porosnicu M; Quinson AM; Crossley K; Luecke S; Lauer UM
Future Oncol; 2022 Aug; 18(24):2627-2638. PubMed ID: 35699077
[TBL] [Abstract][Full Text] [Related]
25. Radiation Attenuates Prostate Tumor Antiviral Responses to Vesicular Stomatitis Virus Containing IFNβ, Resulting in Pronounced Antitumor Systemic Immune Responses.
Udayakumar TS; Betancourt DM; Ahmad A; Tao W; Totiger TM; Patel M; Marples B; Barber G; Pollack A
Mol Cancer Res; 2020 Aug; 18(8):1232-1243. PubMed ID: 32366674
[TBL] [Abstract][Full Text] [Related]
26. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.
Moerdyk-Schauwecker M; Shah NR; Murphy AM; Hastie E; Mukherjee P; Grdzelishvili VZ
Virology; 2013 Feb; 436(1):221-34. PubMed ID: 23246628
[TBL] [Abstract][Full Text] [Related]
27. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
Naik S; Nace R; Barber GN; Russell SJ
Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
[TBL] [Abstract][Full Text] [Related]
28. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
[TBL] [Abstract][Full Text] [Related]
29. Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.
Nelson A; McMullen N; Gebremeskel S; De Antueno R; Mackenzie D; Duncan R; Johnston B
Breast Cancer Res; 2024 May; 26(1):78. PubMed ID: 38750591
[TBL] [Abstract][Full Text] [Related]
30. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ
Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991
[TBL] [Abstract][Full Text] [Related]
31. Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection.
Le Boeuf F; Niknejad N; Wang J; Auer R; Weberpals JI; Bell JC; Dimitroulakos J
Int J Cancer; 2012 Aug; 131(3):E204-15. PubMed ID: 22173567
[TBL] [Abstract][Full Text] [Related]
32. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy.
Janelle V; Brassard F; Lapierre P; Lamarre A; Poliquin L
J Virol; 2011 Jul; 85(13):6513-20. PubMed ID: 21561919
[TBL] [Abstract][Full Text] [Related]
33. The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer.
Schreiber LM; Urbiola C; Das K; Spiesschaert B; Kimpel J; Heinemann F; Stierstorfer B; Müller P; Petersson M; Erlmann P; von Laer D; Wollmann G
Br J Cancer; 2019 Oct; 121(8):647-658. PubMed ID: 31530903
[TBL] [Abstract][Full Text] [Related]
34. Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo.
Cary ZD; Willingham MC; Lyles DS
J Virol; 2011 Jun; 85(12):5708-17. PubMed ID: 21450822
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.
Hadaschik BA; Zhang K; So AI; Fazli L; Jia W; Bell JC; Gleave ME; Rennie PS
Cancer Res; 2008 Jun; 68(12):4506-10. PubMed ID: 18559493
[TBL] [Abstract][Full Text] [Related]
36. Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models.
Capo-chichi CD; Yeasky TM; Heiber JF; Wang Y; Barber GN; Xu XX
Gynecol Oncol; 2010 Feb; 116(2):269-75. PubMed ID: 19932656
[TBL] [Abstract][Full Text] [Related]
37. Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy.
Dold C; Rodriguez Urbiola C; Wollmann G; Egerer L; Muik A; Bellmann L; Fiegl H; Marth C; Kimpel J; von Laer D
Mol Ther Oncolytics; 2016; 3():16021. PubMed ID: 27738655
[TBL] [Abstract][Full Text] [Related]
38. Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy.
Muik A; Dold C; Geiß Y; Volk A; Werbizki M; Dietrich U; von Laer D
J Mol Med (Berl); 2012 Aug; 90(8):959-70. PubMed ID: 22286341
[TBL] [Abstract][Full Text] [Related]
39. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
Shen W; Patnaik MM; Ruiz A; Russell SJ; Peng KW
Blood; 2016 Mar; 127(11):1449-58. PubMed ID: 26712908
[TBL] [Abstract][Full Text] [Related]
40. Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer.
Chang G; Xu S; Watanabe M; Jayakar HR; Whitt MA; Gingrich JR
J Urol; 2010 Apr; 183(4):1611-8. PubMed ID: 20172545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
